文献速递核素与放射性配体治疗

[225Ac]Ac-SibuDAB在前列腺癌患者中的疗效、安全性、血液动力学及213Bi分布研究

Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients.
PubMed 文献 · J Nucl Med · 2025-08-01

这项回顾性研究纳入15例接受[225Ac]Ac-SibuDAB治疗的晚期前列腺癌患者,计划每8周给药6 MBq。15例中9例出现PSA下降,5例PSA下降≥50%;全部患者出现1级口干,1例因3级血小板减少终止治疗。213Bi在给药后迅速分布至尿液,血液中任何时间点均未检出213Bi。

要点

  • 15例重度经治前列腺癌患者接受[225Ac]Ac-SibuDAB,9例PSA下降、5例下降≥50%。
  • 全部患者出现1级口干,1例因3级血小板减少终止治疗。
  • 213Bi在给药后迅速分布至尿液,血液中任何时间点均未检出213Bi。

核心结论

  • [225Ac]Ac-SibuDAB在重度经治前列腺癌患者中显示出疗效,1例患者出现治疗限制性毒性,治疗后仅观察到有限的口干迹象。
  • 应用[225Ac]Ac-SibuDAB后,反冲产生的213Bi迅速分布至尿液中。

研究设计与样本

  • 回顾性研究纳入2021年12月至2024年8月期间接受[225Ac]Ac-SibuDAB治疗的15例前列腺癌患者,计划每8周给予6 MBq。
  • 疗效评估前列腺特异性抗原(PSA)反应,不良事件按常见不良事件评价标准第5.0版分类。
  • 在225Ac/221Fr平衡条件下测定血液药代动力学;在达到225Ac/213Bi平衡前测定血液和尿液样本中的213Bi分布。

主要发现

  • 15例患者共接受25个周期,中位暴露量为6.55 MBq(范围4.65–30.60 MBq)。
  • 15例中12例可获取Gleason评分,其中10例Gleason评分≥8;13例既往接受过[177Lu]Lu-PSMA治疗。
  • 15例中9例出现任何PSA下降,5例PSA下降≥50%。
  • 全部患者出现1级口干;1例因3级血小板减少终止治疗。
  • 在6例患者中评估[225Ac]Ac-SibuDAB血液动力学;在3例患者中进行213Bi血液和尿液分布研究,显示给药后尿液中213Bi净过量显著,后期时间点呈中度过量,血液中任何时间点均无213Bi。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

225Ac-labeled (S)-ibuprofen-diaminobutyric acid-PSMA (SibuDAB) is a novel, albumin-binding compound in prostate-specific membrane antigen (PSMA)-targeted α-therapy of prostate cancer. It showed superior preclinical efficacy results to [225Ac]Ac-PSMA-617. 225Ac decays via multiple α-particle emissions. The full therapeutic potential requires fast tumor uptake and retention of parent and daughter nuclides, such as 213Bi, in the tumor. High decay energies lead to daughter nuclide recoil of the chelator and, therefore, altered pharmacokinetics and potential irradiation of off-target organs. We hereby present clinical efficacy and safety data for [225Ac]Ac-SibuDAB, as well as blood kinetics and the 213Bi distribution between blood and urine samples. Methods: Fifteen prostate cancer patients who received [225Ac]Ac-SibuDAB between December 2021 and August 2024 were included in this retrospective study. Patients were scheduled to receive 6 MBq of [225Ac]Ac-SibuDAB every 8 wk. The prostate-specific antigen (PSA) response was evaluated, and adverse events were categorized according to Common Terminology Criteria for Adverse Events, version 5.0. Blood pharmacokinetics were determined after blood sampling at different time points and measured in 225Ac/221Fr equilibrium. The 213Bi distribution was determined in blood and urine samples before reaching 225Ac/213Bi equilibrium. Results: Fifteen patients received a total of 25 cycles with a median exposure of 6.55 MBq (range, 4.65-30.60 MBq). The Gleason score was available for 12 of the 15 patients, with 10 patients having a Gleason score of 8 or higher. The patients were heavily pretreated, including 13 patients with prior [177Lu]Lu-PSMA therapy. Nine of the 15 patients showed any PSA decline, and 5 of the 15 patients showed a PSA decline of 50% or more. All patients showed grade 1 xerostomia. Treatment was stopped because of grade 3 thrombocytopenia in 1 of the 15 patients. [225Ac]Ac-SibuDAB blood kinetics were evaluated in 6 patients. 213Bi blood and urine distribution studies were conducted on 3 patients and showed a vast net 213Bi excess in urine immediately after application, a moderate excess at later time points, and a lack of 213Bi in blood at any time point. Conclusion: [225Ac]Ac-SibuDAB initial clinical data show efficacy in heavily pretreated prostate cancer patients, with 1 patient experiencing treatment-limiting toxicity. Only limited signs of xerostomia were observed after the treatment. 213Bi generated by recoil is rapidly distributed into urine after application of [225Ac]Ac-SibuDAB.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmitl S, Kretschmer-Chott E, Patronas EM, et al. Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients. J Nucl Med. 2025. PMID: 40473466. doi:10.2967/jnumed.125.269655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。